Category: carcinoid cancer

Lu-177

One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers

May 3, 2016

The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration last week, a decision from the FDA is expected by early 2017.  Additionally, an Expanded

READ MORE
Big Apple NETs_0

June Luncheon with the Experts in New York City for the Carcinoid and Neuroendocrine Tumor Community

April 27, 2016

Carcinoid and neuroendocrine tumor (NET) patients have a unique opportunity to hear from three medical experts during Lunch with the Experts in New York City on Sunday, June 12, 2016.  This special program was initiated and is sponsored by the Big Apple

READ MORE
Sue O’Dorisio, MD_7

OncLive Features Neuroendocrine Tumors in Videos and News Articles

April 14, 2016

Chemotherapy Options in Neuroendocrine Tumors is the latest video to be released in the OncLive series on Neuroendocrine Tumors. Matthew H. Kulke, MD, Director of the Program in Neuroendocrine and Carcinoid-Tumors at Dana-Farber/Brigham and Women’s…

READ MORE
App Carcinoid NETs Updated_2

New and Improved App for Managing Carcinoid Cancer and Neuroendocrine Tumors

March 17, 2016

Have you heard about or downloaded the Carcinoid NETs Health Storylines self-care app? Originally launched last year, the app has been updated recently with lots of improvements based on your feedback!

Developed in partnership with the Carcinoid Cancer…

READ MORE
2015-highlights

10 Highlights of the Year 2015 for the Carcinoid and Neuroendocrine Tumor Community

January 5, 2016

As we begin a new year, the Carcinoid Cancer Foundation looks back on the highlights of 2015 and to a future that we hope will bring greater awareness of carcinoid and neuroendocrine cancers, earlier diagnosis for patients, new treatment options, and …

READ MORE
Carcinoid Syndrome, Lexicon Pharmaceuticals, Telotristat Etiprate Clinical Trial

Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial

August 5, 2015

Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled…

READ MORE
sticky-example

10 Highlights for the Carcinoid and Neuroendocrine Tumor Community

June 12, 2015
  • PET/CT using Gallium-68 DOTATOC captures hidden source of neuroendocrine cancer. “An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society
READ MORE
Michael Farris Golden Rule

DENIED: Michael Farris’ Journey with Insurance for Neuroendocrine Cancer Treatment

June 8, 2015

The good news is the very positive result at the end – but the road to getting insurance coverage for Michael Farris’ participation in the PRRT (peptide receptor radionuclide therapy) clinical trial at Excel Diagnostics in Houston, Texas, was fraught…

READ MORE
Carcinoid_NET Specialists collage 2015

March 30 Is National Doctors’ Day

March 29, 2015

March 30 is NATIONAL DOCTORS’ DAY. In recognition of carcinoid/neuroendocrine tumor (NET) doctors – you are our heroes and superheroes!! Pictured are some of the NET specialists throughout the United States.

Pictured by columns, left to right, top …

READ MORE
Cy Ball, carcinoid, SoundCloud music

Cancer and Meditation by Cy Ball

March 19, 2015

Our guest blogger this month is Cy Ball, a retired computer software developer, enthusiastic fly fisherman, and music producer. He was diagnosed with carcinoid cancer about a year after his retirement, with a primary tumor in his intestinal area (still…

READ MORE